Oruka Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for oncology and immuno-inflammatory diseases. Leveraging a proprietary Humabody® technology platform, the company engineers small-format, multi-specific biologics designed to improve tissue penetration, target engagement and safety profiles. Oruka’s product candidates aim to combine the benefits of traditional antibody therapies with enhanced modularity, enabling rapid optimization of binding affinity, half-life extension and multi-target specificity.
The company’s pipeline includes wholly owned programs and partnered assets addressing key targets in immuno-oncology, such as checkpoint modulators, as well as cytokine-focused therapies for autoimmune and inflammatory disorders. Oruka’s Humabody platform harnesses single-domain antibody fragments derived from heavy-chain-only antibodies, which are recombinantly produced in microbial systems to yield stable, high-purity drug candidates. This innovative approach underpins both in-house development efforts and collaborations with leading pharmaceutical organizations.
Oruka has established strategic partnerships to accelerate the advancement of its Humabody molecules. These collaborations include research and licensing agreements with global biopharma companies, through which Oruka applies its platform to create novel multi-specific therapeutics. Partnered programs benefit from joint expertise in areas such as target validation, clinical development and manufacturing scale-up, enabling more efficient progression toward regulatory milestones and potential commercialization.
Founded in 2008 and originally known as Crescendo Biologics, Oruka Therapeutics rebranded in 2021 to reflect its evolving strategic vision. Headquartered in Cambridge, U.K., the company also maintains research operations in key biotech hubs to support discovery and translational studies. Oruka’s leadership team comprises experienced industry executives with backgrounds spanning global pharmaceutical and biotechnology sectors. Guided by a seasoned board of directors and scientific advisors, the company is positioned to advance its innovative pipeline toward clinical proof-of-concept and beyond.
AI Generated. May Contain Errors.
Free ORKA Stock Alerts